- Duración
- 18/4/2020 - 31/12/2021
- Coordinador
- Technische Universität München
- Financiadores
- EIT Health
The current restrictions related to SARS-CoV-2 impose a major burden on our healthcare system, society and economy. A significant gap is the lack of test systems to identify people already immune to SARS-CoV-2 and who would thus be protected from re-infection. While development of numerous serological assays is underway worldwide, it remains unknown whether the measured immune responses are truly protective. CoViproteHCt addresses this gap by rapidly developing and validating such urgently needed assays to characterize protective immune responses that can then be used to identify protected individuals, in particular healthcare personnel (HCP) working with COVID-19 patients and in other critical areas. The developed assays can subsequently be adapted by companies and academic partners throughout the world within weeks.
This approach will allow the selective release of HCP from quarantine restrictions and their subsequent return to work, thus stabilizing our healthcare system and economy.
Funding
678.671 €
Nuestro equipo
Equipo ISGlobal
-
Carlota Dobaño Research Professor -
Alberto García-Basteiro Assistant Research Professor -
Alfredo Mayor Associate Research Professor -
Gemma Moncunill Assistant Research Professor
Otros proyectos
Ver proyectos pasadosCOMBACTE
Combatiendo la Resistencia Bacteriana en Europa
Evaluación de estrategias para la erradicación de la enfermedad del Pian
Erradicación del Pian
Novel Marine Biomolecules against Biofilm (NoMorFilm)
Application to medical devices
www.nomorfilm.euCOMBACTE-CARE
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
https://www.imi.europa.eu/content/combacte-carePrioritising Antimicrobial Resistance: establishing an interdisciplinary International Research Partnership to tackle an evolving global health threat
An interdisciplinary International Research Partnership to tackle an evolving global health threat
Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.
New metal-antibiotics for patients with cystic fibrosis
HU-MEN (High frequency Ultrasound-based MENingitis screening)
Non-invasive ultrasound-based screening for meningitis: Proof-of concept in infants
Xpatial-TB
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
WHIP3TB
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals
https://clinicaltrials.gov/ct2/show/NCT02980016New antibacterial agents against 'Acinetobacter baumannii'
Search for new target proteins and use of antibacterial or inhibitory peptides against resistance mechanisms in 'Acinetobacter baumannii'
Desarrollo de nuevos metaloantibióticos frente a patógenos causantes de infecciones crónicas en pacientes con fibrosis quística
VINCI
Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique
INTE-AFRICA
Integrating and decentralizing diabetes and hypertension services in Africa
http://inteafrica.org/AVATAR
Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.
SAFE - Superbug Awareness For Education
https://safeinitiative.eu/COVID-PREG
Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo
SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT)
Estudio piloto para evaluar el potencial de la ivermectina para reducir la transmisión de COVID-19
http://www.saintproject.org